DAPT-strategie bij HBR-patiënten die complexe PCI ondergaan na ACS: Tweede-fase bèta-testen van een patiëntenbeslissingshulpmiddel (BETA-DAPT)
Duale Antiplatelettherapiestrategie bij Patiënten met Hoog Bloedingrisico die Complexe Percutane Coronaire Interventie Onderhebben na een Acuut Coronair Syndroom: Tweede Fase Betatest van een Patiëntenbeslissingshulpmiddel
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.
In this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria (Patients)
- Adults aged 18 years or older
- Hospitalized on the coronary care unit ward at the Montreal Heart Institute (MHI)
- Acute coronary syndrome (ACS) during the current episode of care, treated with PCI and placement of one or more coronary stents
- High bleeding risk based on PRECISE-HBR score and high thrombotic risk, with both risks considered of comparable clinical importance by the treating medical team
Inclusion Criteria (Clinicians)
- Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants
Exclusion Criteria (Patients)
- Receiving therapeutic anticoagulation
- Planned cardiac surgery during the same episode of care
- Prior history of coronary stent thrombosis
- Antiphospholipid syndrome or known thrombophilia
- Unable to participate in shared decision-making
- Unable to understand spoken and written French or English
- Concurrent participation in another study (followed within another research protocol)
- Transferred from another center for reasons other than coronary angiography at MHI and expected to return to the referring center for ongoing care (i.e., "fly-in/fly-out" patients)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: High bleeding risk patients treated with complex PCI in the context of ACS
The intervention is the use of the Patient Decision Aid (PDA) to support shared decision-making between patients and clinicians after PCI, assessed using questionnaires capturing multiple dimensions of decision quality. No pharmacologic treatment is administered as part of the study; exposure consists solely of complete use of the PDA according to the protocol. The study includes a single pre-post group, no interim analyses are planned given the limited project duration, and a single beta-testing phase will be conducted. |
Patient decision aid to support shared decision-making between patients and clinicians by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Decisional Conflict (DCS-LL) After Use of the Patient Decision Aid (PDA)
Tijdsspanne: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
Change in total score on the low-literacy Decisional Conflict Scale (DCS-LL; Ottawa Hospital Research Institute), comparing pre-PDA vs post-PDA completion. Lower scores indicate less decisional conflict. |
Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Antiplatelet Strategy Knowledge Score After PDA Use
Tijdsspanne: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
Change in total score on an adapted OHRI knowledge questionnaire assessing understanding of bleeding and thrombotic risks and DAPT options, comparing pre-PDA vs post-PDA completion. |
Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
|
Preparation for Decision-Making (PrepDM) Score After PDA Use
Tijdsspanne: Immediately post-PDA completion (Day 0, index hospitalization).
|
Total score on the Preparation for Decision Making (PrepDM; OHRI) questionnaire completed after PDA use. Higher scores indicate greater perceived preparedness to make a decision with the clinician. |
Immediately post-PDA completion (Day 0, index hospitalization).
|
|
Patient Acceptability Score of the PDA in Routine Clinical Use
Tijdsspanne: Immediately post-PDA completion (Day 0, index hospitalization).
|
Total score on an OHRI acceptability questionnaire completed after PDA use, reflecting perceived relevance, clarity, length, and overall acceptability in the clinical setting. |
Immediately post-PDA completion (Day 0, index hospitalization).
|
|
Patient Refusal Rate to Use the PDA and Reasons for Refusal
Tijdsspanne: Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).
|
Number and proportion of eligible patients who personally refuse participation/PDA use, and categorization of documented reasons for refusal (e.g., not interested, too tired, overwhelmed, language barriers, time constraints). |
Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).
|
|
Agreement Between Patient-Preferred Antiplatelet Strategy and Strategy Prescribed at Hospital Discharge
Tijdsspanne: At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).
|
Proportion of agreement between (a) the antiplatelet strategy preferred by the patient as identified through the PDA and (b) the antiplatelet strategy documented on the discharge prescription/orders. |
At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).
|
|
Clinician Usability of the PDA (French System Usability Scale, F-SUS)
Tijdsspanne: Day 0 (immediately after PDA use with an included patient)
|
Total score on the French System Usability Scale (F-SUS) completed by clinicians after using the PDA with an included patient in routine clinical care. Higher scores indicate better usability. |
Day 0 (immediately after PDA use with an included patient)
|
|
Clinician Refusal Rate to Use the PDA and Reasons for Non-Use
Tijdsspanne: Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).
|
Number and proportion of eligible patient encounters in which the clinician declines to use the PDA when asked, along with categorization of documented reasons (e.g., time constraints, clinical instability, workflow barriers, clinician preference). |
Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Exploratory Subgroup Effects on Decisional Conflict Scores Low Litteracy (DCS-LL) Questionnaire
Tijdsspanne: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
Exploratory assessment of whether changes in DCS-LL differ by prespecified characteristics: age (<70 vs ≥70 years), sex (male vs female), mother tongue (French vs English), education level (university vs lower) and prior percutaneous intervention with stent (yes or no). Analyses are descriptive/exploratory. |
Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-3682
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .